CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "SITAGLIPTIN PHOSPHATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED

石 藥 集 團 有 限 公 司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

"SITAGLIPTIN PHOSPHATE TABLETS"

OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the "Board") of CSPC Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the "Sitagliptin Phosphate Tablets" (100mg) (the "Product") developed by CSPC Ouyi Pharmaceutical Co., Ltd.*（石藥集團歐 意藥業有限公司）, a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

As a dipeptidyl peptidase-4 (DPP4) inhibitor, sitagliptin phosphate is indicated for the improvement of glycemic control in patients with type 2 diabetes. Compared with other hypoglycemic drugs, sitagliptin phosphate has the advantages of lower risk of hypoglycemia, no significant weight gain, less gastrointestinal adverse effects and improvement of β-cell function. It can be used in combination with metformin hydrochloride, sulfonylureas and insulin to improve glycemic control in patients with type 2 diabetes where single drug treatment of the above drugs or sulfonylureas or insulin in combination with metformin hydrochloride failed to achieve glycemic control.

The approval of the Product further enriches the Group's product portfolio for metabolism diseases and offers new option to patients with type 2 diabetes.

By order of the Board

CSPC Pharmaceutical Group Limited

Cai Dongchen

Chairman

Hong Kong, 11 May 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

• For identification purpose only